niacinamide has been researched along with ly-2157299 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Albuquerque, M; Benhadji, KA; de Gramont, A; Dos Santos, C; Faivre, S; Neuzillet, C; Paradis, V; Raymond, E; Serova, M; Tijeras-Raballand, A | 1 |
| Han, C; Ungerleider, N; Wu, T; Yao, L; Zhang, J | 1 |
2 other study(ies) available for niacinamide and ly-2157299
| Article | Year |
|---|---|
Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Caspase 3; Cell Line, Tumor; Cell Proliferation; Female; Hep G2 Cells; Humans; Immunohistochemistry; Indoles; Ki-67 Antigen; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Pyrazoles; Pyrroles; Quinolines; Signal Transduction; Sorafenib; Sunitinib; Transforming Growth Factor beta1 | 2015 |
TGFβ signaling confers sorafenib resistance via induction of multiple RTKs in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Liver; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyrazoles; Quinolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sorafenib; Transforming Growth Factor beta | 2017 |